WASHINGTON - Sen. Daniel Moynihan, chairman of the Senate Finance Committee, has unveiled a proposed health care plan that omits a prescription drug benefit for Medicare, along with the accompanying drug price control mechanisms that would be necessary to offset the cost of the benefit.

The New York Democrat omitted the Medicare drug benefit because he feared it would be too expensive, a Finance Committee staff member told BioCentury. As a result, price control mechanisms that have been included in other bills to offset the costs of the benefit, such as a breakthrough drug council, drug price rebates and a Medicare blacklist, are also absent from Moynihan's bill.

Reconcile with Kennedy